secwatch / observer
8-K filed June 16, 2022, 7:59 PM ET ticker RNTX CIK 0001420565
other material confidence high sentiment negative materiality 0.70

Aileron appoints interim CFO; shareholders approve reverse stock split (1:5–1:25)

Rein Therapeutics, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Susan L. Drexler

interim chief financial officer
RNTX · Rein Therapeutics, Inc.
Effective
2022-06-16
Filed
June 16, 2022, 7:59 PM ET
On June 15, 2022, the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Susan L. Drexler, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of June 16, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Susan L. Drexler was appointed as interim chief financial officer at Rein Therapeutics, Inc..

Action
appointed
Role
interim chief financial officer
Exact text from the filing
On June 15, 2022, the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Susan L. Drexler, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of June 16, 2022.
View on SEC.gov

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-175284
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.